Abstract
Since the finding in 1986 that tumor-infiltrating lymphocytes (TILs) were 50-100 times more effective than lymphokine-activated killer cells in killing cancer cells, TILs have attracted great attention in cancer research. Recently (2019) the FDA approved LN-145 as a cancer therapy based on autologous tumor-infiltrating lymphocytes, thus reaffirming that TILs have great potential as an effective cancer treatment. Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world and effective adaptive cell therapy is lacking.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call